Evaluation of the Drug-drug Interaction Between FosD and Verapamil When Taken Together in Healthy Volunteers

Launched by ASTRAZENECA · Sep 8, 2010

Keywords

ClinConnect Summary

An Open-label, Single-Centre Study to Assess the Pharmacokinetics of R406 in Healthy Volunteers when Fostamatinib Disodium 150 mg is Administered Alone and in Combination with Verapamil.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Weight of at least 50 kg (110 lbs) and body mass index (BMI) between 18 and 35 kg/m2, inclusive.
• • Females must be of non-childbearing potential
• Exclusion Criteria:
• • History of clinically significant disease or disorder or presence of GI, hepatic or renal disease
• • Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of the drug
• • Any clinically significant abnormalities in lab safety tests or vital signs as results as judged by the Investigator
• • Use of prescription or over-the-counter drugs within 2 weeks of first administration of investigational product
• • Current smokers or use of nicotine products within 1 month prior to enrollment